
Pangea Biomed adds $5M in additional funding for its RNA-Seq/AI based multi-cancer response predictor technology
The funding extension, which brings the total seed round to $12M, will advance Pangea’s goal…
The funding extension, which brings the total seed round to $12M, will advance Pangea’s goal…
Graphite Bio, a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene…
PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced its HiFi sequencing…
Researchers at Exai Bio and UCSF have released data demonstrating that Exai’s novel, RNA-based liquid…
Dolomite Bio launches the RNAdia 2.0 reagent kit for single cell research, as part of…
With the debut of its novel single-cell solution and its first Grant Program, Scipio bioscience…
Collaboration will leverage Envisagenics’ SpliceCore® AI platform for accelerated discovery and development of oncology therapeutic…
The main aim of the collaboration is to be able to quickly identify lead genes…
New insights possible with single-cell and spatial nanopore sequencing Oxford Nanopore Technologies plc (Oxford…
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced today…